Clinical Scorecard: The 51st Annual Conference of the European Society for Blood and Marrow Transplantation: Recognition of Van Bekkum Award Recipients

At a Glance

Key Highlights

• Haploidentical stem cell transplantation shows survival advantage in high-risk acute myeloid leukemia with KIR epitope incompatibility.
• Mesenchymal stem cells are effective for treating severe acute and extensive chronic graft-versus-host disease.
• Defibrotide prophylaxis significantly reduces hepatic veno-occlusive disease and related complications in high-risk pediatric patients.

Guideline-Based Recommendations

Diagnosis

• Utilize genetic profiling including NOD2/CARD15 mutations to assess risk of GvHD and transplant-related mortality.
• Employ gene expression profiling to evaluate dendritic cell responses to infections such as Aspergillus fumigatus.
• Monitor inhibitory KIR-ligand mismatching status to predict relapse risk post cord blood transplantation.

Management

• Consider allogeneic stem cell transplantation in first complete remission for patients with poor prognosis myelodysplastic syndromes.
• Use mesenchymal stem cells for treatment of severe acute and chronic GvHD.
• Administer defibrotide prophylactically in children at high risk to prevent hepatic veno-occlusive disease.
• Apply T-cell engineering approaches including chimeric antigen receptor (CAR) T-cells and TCR gene editing for targeted immunotherapy without inducing GvHD.

Monitoring & Follow-up

• Regularly assess for disease relapse and transplant-related mortality, especially in recipients with high-risk genetic polymorphisms.
• Monitor immune reconstitution and persistence of engineered T-cells post-transplantation.
• Evaluate clinical response and adverse events following immuno-gene therapies and cellular treatments.

Risks

• Increased risk of GvHD and transplant-related mortality associated with NOD2/CARD15 mutations in donors and recipients.
• Potential for disease relapse influenced by inhibitory KIR-ligand mismatching and genetic factors.
• Complications such as hepatic veno-occlusive disease in high-risk pediatric populations without prophylaxis.

Patient & Prescribing Data

Patients undergoing hematopoietic stem cell transplantation for hematologic malignancies and immune disorders

Emerging therapies including gene-marked autologous transplantation, immuno-gene therapy with tumor mRNA transfected dendritic cells, and engineered T-lymphocytes demonstrate promising efficacy and safety profiles; prophylactic and therapeutic use of mesenchymal stem cells and defibrotide improve transplant outcomes and reduce complications.

Clinical Best Practices

• Incorporate genetic and immunologic profiling to personalize transplant strategies and predict complications.
• Utilize haploidentical donors with KIR epitope incompatibility to improve survival in poor-risk acute myeloid leukemia.
• Implement prophylactic defibrotide in pediatric patients at high risk for hepatic veno-occlusive disease.
• Apply mesenchymal stem cell therapy for refractory graft-versus-host disease.
• Adopt advanced T-cell engineering techniques such as CAR T-cell therapy and TCR gene editing to enhance anti-leukemia activity while minimizing GvHD.

References

• European Society for Blood and Marrow Transplantation Annual Meeting